Long non‑coding RNA SNHG17 enhances the aggressiveness of C4‑2 human prostate cancer cells in association with β‑catenin signaling

Zhao,Haijun; Dong,Haijing; Wang,Peng; Zhu,Hai

doi:10.3892/ol.2021.12733

Long non‑coding RNA SNHG17 enhances the aggressiveness of C4‑2 human prostate cancer cells in association with β‑catenin signaling

Authors:
- Haijun Zhao
- Haijing Dong
- Peng Wang
- Hai Zhu
View Affiliations

Affiliations: Department of Urology, Qingdao Municipal Hospital Affiliated to Qingdao Medical College of Qingdao University, Qingdao, Shandong 266071, P.R. China
Published online on: April 13, 2021 https://doi.org/10.3892/ol.2021.12733
Article Number: 472
Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Long non‑coding (lnc) RNAs have emerged as important regulators of cancer development and progression. Several lncRNAs have been reported to be associated with prostate cancer (PCa); however, the involvement of lncRNA SNHG17 in PCa remains unclear. In the present study, the mRNA expression level of SNHG17 in 58 pairs of PCa tumor samples and adjacent non‑tumor tissues, as well as in PCa tumor cell lines was analyzed. The regulatory effect of SNHG17 on the oncogenic phenotypes of the C4‑2 tumor cell line was also investigated. The clinicopathological analysis revealed that SNHG17 mRNA expression level was increased in the PCa tumor samples, and its high expression levels were associated with poor patient outcomes, indicating that SNHG17 may act as a biomarker for the prognosis of PCa. SNHG17 mRNA expression level was also increased in different PCa tumor cell lines. Functionally, SNHG17 increased C4‑2 tumor cell growth and aggressiveness by stimulating tumor cell proliferation, survival, invasion and resistance to chemotherapy. Furthermore, SNHG17 promoted in vivo tumor growth in a xenograft mouse model. Notably, the SNHG17‑induced in vitro and in vivo oncogenic effects were associated with activation of the β‑catenin pathway. The results from the present study revealed that lncRNA SNHG17 could be an important regulator in the oncogenic properties of human PCa and may; therefore, represent a potential PCa therapeutic target.

View Figures

View References

1	Global Burden of Disease Cancer Collaboration, ; Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, et al: Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the global burden of disease study. JAMA Oncol. 3:524–548. 2017. View Article : Google Scholar : PubMed/NCBI
2	Chandrasekar T, Yang JC, Gao AC and Evans CP: Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Andro Urol. 4:365–380. 2015.PubMed/NCBI
3	Mansinho A, Macedo D, Fernandes I and Costa L: Castration-Resistant prostate cancer: Mechanisms, targets and treatment. Adv Exp Med Biol. 1096:117–133. 2018. View Article : Google Scholar : PubMed/NCBI
4	Aird J, Baird AM, Lim MCJ, McDermott R, Finn SP and Gray SG: Carcinogenesis in prostate cancer: The role of long non-coding RNAs. Noncoding RNA Res. 3:29–38. 2018. View Article : Google Scholar : PubMed/NCBI
5	Weiss M, Plass C and Gerhauser C: Role of lncRNAs in prostate cancer development and progression. Biol Chem. 395:1275–1290. 2014. View Article : Google Scholar : PubMed/NCBI
6	Zhang T, Hu H, Yan G, Wu T, Liu S, Chen W, Ning Y and Lu Z: Long non-coding RNA and breast cancer. Technol Cancer Res Treat. 18:15330338198438892019. View Article : Google Scholar : PubMed/NCBI
7	Wu J, Cheng G, Zhang C, Zheng Y, Xu H, Yang H and Hua L: Long noncoding RNA LINC01296 is associated with poor prognosis in prostate cancer and promotes cancer-cell proliferation and metastasis. Onco Targets Ther. 10:1843–1852. 2017. View Article : Google Scholar : PubMed/NCBI
8	Petrovics G, Zhang W, Makarem M, Street JP, Connelly R, Sun L, Sesterhenn IA, Srikantan V, Moul JW and Srivastava S: Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. Oncogene. 23:605–611. 2004. View Article : Google Scholar : PubMed/NCBI
9	Wang L, Han S, Jin G, Zhou X, Li M, Ying X, Wang L, Wu H and Zhu Q: Linc00963: A novel, long non-coding RNA involved in the transition of prostate cancer from androgen-dependence to androgen-independence. Int J Oncol. 44:2041–2049. 2014. View Article : Google Scholar : PubMed/NCBI
10	Ma Z, Gu S, Song M, Yan C, Hui B, Ji H, Wang J, Zhang J, Wang K and Zhao Q: Long non-coding RNA SNHG17 is an unfavourable prognostic factor and promotes cell proliferation by epigenetically silencing P57 in colorectal cancer. Mol Biosyst. 13:2350–2361. 2017. View Article : Google Scholar : PubMed/NCBI
11	Xu T, Yan S, Jiang L, Yu S, Lei T, Yang D, Lu B, Wei C, Zhang E and Wang Z: Gene amplification-driven long noncoding RNA SNHG17 regulates cell proliferation and migration in human non-small-cell lung cancer. Mol Ther Nucleic Acids. 17:405–413. 2019. View Article : Google Scholar : PubMed/NCBI
12	Zhang G, Xu Y, Wang S, Gong Z, Zou C, Zhang H, Ma G, Zhang W and Jiang P: LncRNA SNHG17 promotes gastric cancer progression by epigenetically silencing of p15 and p57. J Cell Physiol. 234:5163–5174. 2019. View Article : Google Scholar : PubMed/NCBI
13	Willert K and Nusse R: Wnt proteins. Cold Spring Harb Perspect Biol. 4:a0078642012. View Article : Google Scholar : PubMed/NCBI
14	Zhan T, Rindtorff N and Boutros M: Wnt signaling in cancer. Oncogene. 36:1461–1473. 2017. View Article : Google Scholar : PubMed/NCBI
15	Murillo-Garzon V and Kypta R: WNT signalling in prostate cancer. Nat Rev Urol. 14:683–696. 2017. View Article : Google Scholar : PubMed/NCBI
16	Kumar A, Zloza A, Moon RT, Watts J, Tenorio AR and Al-Harthi L: Active beta-catenin signaling is an inhibitory pathway for human immunodeficiency virus replication in peripheral blood mononuclear cells. J Virol. 82:2813–2820. 2008. View Article : Google Scholar : PubMed/NCBI
17	Gedaly R, Galuppo R, Daily MF, Shah M, Maynard E, Chen C, Zhang X, Esser KA, Cohen DA, Evers BM, et al: Targeting the Wnt/beta-catenin signaling pathway in liver cancer stem cells and hepatocellular carcinoma cell lines with FH535. PLoS One. 9:e992722014. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Krakhmal NV, Zavyalova MV, Denisov EV, Vtorushin SV and Perelmuter VM: Cancer invasion: Patterns and mechanisms. Acta Naturae. 7:17–28. 2015. View Article : Google Scholar : PubMed/NCBI
20	Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 351:1513–1520. 2004. View Article : Google Scholar : PubMed/NCBI
21	Lohiya V, Aragon-Ching JB and Sonpavde G: Role of chemotherapy and mechanisms of resistance to chemotherapy in metastatic Castration-Resistant prostate cancer. Clin Med Insights Oncol. 10 (Suppl 1):S57–S66. 2016.PubMed/NCBI
22	Ramnarine VR, Kobelev M, Gibb EA, Nouri M, Lin D, Wang Y, Buttyan R, Davicioni E, Zoubeidi A and Collins CC: The evolution of long noncoding RNA acceptance in prostate cancer initiation, progression, and its clinical utility in disease management. Euro Urol. 76:546–559. 2019. View Article : Google Scholar : PubMed/NCBI
23	Du Y, Wei N, Hong J and Pan W: Long non-coding RNASNHG17 promotes the progression of breast cancer by sponging miR-124-3p. Cancer Cell Int. 20:402020. View Article : Google Scholar : PubMed/NCBI
24	Eggener SE, Badani K, Barocas DA, Barrisford GW, Cheng JS, Chin AI, Corcoran A, Epstein JI, George AK, Gupta GN, et al: Gleason 6 prostate cancer: Translating biology into population health. J Urol. 194:626–634. 2015. View Article : Google Scholar : PubMed/NCBI
25	Takeuchi H, Ohori M and Tachibana M: Clinical significance of the prostate-specific antigen doubling time prior to and following radical prostatectomy to predict the outcome of prostate cancer. Mol Clin Oncol. 6:249–254. 2017. View Article : Google Scholar : PubMed/NCBI
26	Shulman MJ, Karam JA and Benaim EA: Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer. Urology. 63:732–736. 2004. View Article : Google Scholar : PubMed/NCBI
27	Luqmani YA: Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract. 14 (Suppl 1):S35–S48. 2005. View Article : Google Scholar : PubMed/NCBI
28	Li JF, Li WH, Xue LL and Zhang Y: Long non-coding RNA PICART1 inhibits cell proliferation by regulating the PI3K/AKT and MAPK/ERK signaling pathways in gastric cancer. Eur Rev Med Pharmacol Sci. 23:588–597. 2019.PubMed/NCBI
29	Rani N, Nowakowski TJ, Zhou H, Godshalk SE, Lisi V, Kriegstein AR and Kosik KS: A primate lncRNA mediates notch signaling during neuronal development by sequestering miRNA. Neuron. 90:1174–1188. 2016. View Article : Google Scholar : PubMed/NCBI
30	Hu XY, Hou PF, Li TT, Quan HY, Li ML, Lin T, Liu JJ, Bai J and Zheng JN: The roles of Wnt/β-catenin signaling pathway related lncRNAs in cancer. Int J Biol Sci. 14:2003–2011. 2018. View Article : Google Scholar : PubMed/NCBI
31	Yu J, Han Z, Sun Z, Wang Y, Zheng M and Song C: LncRNA SLCO4A1-AS1 facilitates growth and metastasis of colorectal cancer through β-catenin-dependent Wnt pathway. J Exp Clin Cancer Res. 37:2222018. View Article : Google Scholar : PubMed/NCBI
32	Tian Z, Yang G, Jiang P, Zhang L, Wang J and Sun S: Long non-coding RNA Sox4 promotes proliferation and migration by activating Wnt/β-catenin signaling pathway in osteosarcoma. Pharmazie. 72:537–542. 2017.PubMed/NCBI
33	Guo JC, Yang YJ, Zheng JF, Zhang JQ, Guo M, Yang X, Jiang XL, Xiang L, Li Y, Ping H and Zhuo L: Silencing of long noncoding RNA HOXA11-AS inhibits the Wnt signaling pathway via the upregulation of HOXA11 and thereby inhibits the proliferation, invasion, and self-renewal of hepatocellular carcinoma stem cells. Exp Mol Med. 51:1–20. 2019. View Article : Google Scholar
34	Kim U, Kim CY, Lee JM, Ryu B, Kim J, Shin C and Park JH: Pimozide inhibits the human prostate cancer cells through the generation of reactive oxygen species. Front Pharmacol. 10:15172020. View Article : Google Scholar : PubMed/NCBI
35	Takeuchi H, Taoka R, Mmeje CO, Jinesh GG, Safe S and Kamat AM: CDODA-Me decreases specificity protein transcription factors and induces apoptosis in bladder cancer cells through induction of reactive oxygen species. Urol Oncol. 34:337.e11–8. 2016. View Article : Google Scholar : PubMed/NCBI